<DOC>
	<DOCNO>NCT00451633</DOCNO>
	<brief_summary>A randomized , double blind , placebo-controlled study employ mixed parallel group fix sequence cross-over design . Patients randomize one two treatment group ( 'E2007 ' 'Placebo ' ) 1:1 ratio receive investigational drug treatment concomitant standard individualize anti-Parkinsonian therapy total six week . Investigational drug treatment patient E2007 treatment group start 2 mg E2007 o.d . escalate 4 mg E2007 o.d . three week .</brief_summary>
	<brief_title>The Effect Of E2007 On Pharmacodynamic Responses To Levodopa Among Patients With Parkinson 's Disease Who Experience Dyskinesia And Motor Fluctuations</brief_title>
	<detailed_description />
	<mesh_term>Parkinson Disease</mesh_term>
	<mesh_term>Dyskinesias</mesh_term>
	<mesh_term>Levodopa</mesh_term>
	<criteria>INCLUSION CRITERIA : Patients eligible study meet follow inclusion criterion . Eligibility check screen reconfirmed start investigational drug dose Day 1 ( ie , completion review predosing patient diary baseline assessment ) . 1 . Men woman age 30 80 year , inclusive . 2 . A diagnosis idiopathic Parkinson 's disease . Patients fulfill UK Parkinson 's Disease Society Brain Bank clinical diagnostic criterion ( Queen Square criterion ) rating 2.4 Hoehn &amp; Yahr scale `` '' state . 3 . Receiving regimen antiParkinsonian treatment optimize ( accord Investigator 's opinion ) stable least four week baseline . The regimen consider stable 'as require ' 'on demand ' dose routinely use regular use apomorphine liquid form levodopa . 4 . Taking levodopa least three time wake day ( include bedtime nighttime dos ) demonstrable response levodopa dose . 5 . Consistently experience clinicallyrelevant , peakeffect levodopainduced dyskinesias 'on ' period follow morning dose levodopa . Patients : 1. score .2 Questions 32 33 full UPDRS screening . 2. least 3 h 'on ' time dyskinesias average per day record patient diary baseline , 1 h within 4 h follow first morning dose levodopa . 6 . Consistently experience endofdose motor fluctuation . Patients : 1. score .1 Question 39 full UPDRS screening . 2. least 1.5 h 'off ' time average per day record patient diary baseline . 7 . Capable adhere protocol requirement provide write informed consent . EXCLUSION CRITERIA : Patients meet follow exclusion criterion eligible study . Eligibility check Screening visit reconfirm start investigational drug dose Day 1 ( i.e. , completion review predosing patient diary baseline assessment ) . All exclusion criterion must observe . 1 . A history drug alcohol abuse . 2 . A history suicide attempt suicidal ideation within past year . 3 . Receiving antipsychotic treatment history psychotic symptom require antipsychotic treatment within past year . Patients take antidepressant medication enter study provide regimen stable . 4 . Receiving treatment monoamine oxidase ( MAO ) B inhibitor ( e.g. , selegiline , rasagiline ) . 5 . Receiving treatment medication know induce CYP3A4 activity . 6 . Receiving treatment medication believe effect levodopainduced dyskinesia ( e.g. , amantadine , dextromethorphan , clozapine , olanzapine , quetiapine ) . 7 . Receiving treatment medication know exacerbate dyskinesia ( eg , sodium valproate , CNS stimulant ) . 8 . Failing respond specify levodopa challenge , levodopa challenge medically appropriate . 9 . Experiencing dyskinesia unrelated peak levodopa effect ( e.g. , `` DID '' pattern ) . 10 . Previous stereotactic surgery ( e.g. , pallidotomy , subthalamic nucleus deep brain stimulation ) Parkinson 's disease . 11 . Having receive investigational product within four week lead Screening participate previous study E2007 . 12 . Clinically significant cognitive impairment ( minimental state examination [ MMSE ] &lt; 26 fulfil DSM IV criterion dementia due Parkinson 's disease ) . 13 . Active hepatic disease , significantly reduce hepatic function significantly elevate liver enzyme ( abnormal bilirubin serum transaminase level 1.5 time upper limit normal range ) . 14 . Clinically significant ECG abnormality , include prolonged QT interval ( define QTc .450 msec ) . 15 . Narrowangle glaucoma . 16 . Conditions affect peripheral central sensory system could interfere pharmacodynamic evaluation effect levodopa . 17 . Women pregnant lactating , intend become pregnant within two month completion study . 18 . Women childbearing potential agree use adequate nonhormonal contraception ( e.g. , intrauterine device , condom spermicide ) throughout study . 19 . A history drug hypersensitivity , especially hypersensitivity component investigational product medication use levodopa challenge . 20 . A history melanoma suspicious , undiagnosed skin lesion . 21 . Any condition could , opinion Investigator , place patient increase risk likely prevent completion study .</criteria>
	<gender>All</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>October 2013</verification_date>
</DOC>